Ekwall E, Jonsson M
Scand J Infect Dis. 1984;16(1):99-102. doi: 10.3109/00365548409068414.
52 convalescent carriers of Salmonellae (n = 25) and Shigellae (n = 27) were treated with a 4-week course of either co-trimoxazole or the combination pivmecillinam/pivampicillin. 84% of the salmonella isolates and 89% of the shigella were resistant to one or more antibiotics. Sulphonamide resistance was observed in 52 and 58% of the strains, respectively. 12 and 44% of the isolates, respectively, were resistant to ampicillin. All were sensitive to mecillinam and all except 2 were sensitive to co-trimoxazole. In salmonella carriers, co-trimoxazole was successful in 54% of the subjects and pivmecillinam/pivampicillin in 58%. Co-trimoxazole cured 83% of the shigella carriers and pivmecillinam/pivampicillin 87%. Shigella carriers responded to therapy promptly. Concurrent biliary disease or diverticulosis adversely affected the prognosis in salmonella carriers.
52名沙门氏菌(n = 25)和志贺氏菌(n = 27)的恢复期带菌者接受了为期4周的复方新诺明或匹美西林/匹氨西林联合治疗。84%的沙门氏菌分离株和89%的志贺氏菌对一种或多种抗生素耐药。分别有52%和58%的菌株对磺胺类药物耐药。分别有12%和44%的分离株对氨苄西林耐药。所有菌株对美西林敏感,除2株外所有菌株对复方新诺明敏感。在沙门氏菌带菌者中,复方新诺明治疗成功率为54%,匹美西林/匹氨西林为58%。复方新诺明治愈了83%的志贺氏菌带菌者,匹美西林/匹氨西林治愈了87%。志贺氏菌带菌者对治疗反应迅速。并发胆道疾病或憩室病对沙门氏菌带菌者的预后有不利影响。